Skip to main content

May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?

Buy Article:

$55.00 plus tax (Refund Policy)

In an aging population vascular disorders well exemplified by the chronic limb ischemia, chronic heart failure, cerebral ischemia and age-related macular degeneration represent a serious medical and socio-economical problem. While there is always a not easily identifiable first pathogenic noxa, all of these diseases are characterized by ischemia, chronic inflammation and tissue degeneration. Orthodox medicine has provided several optimal drugs targeting various pathological situations but, even with their concomitant applications, it is not possible to reduce the chronic oxidative stress. Here it is proposed to associate the approach of ozonated autohemotherapy as a modifier of the biological response capable to block the pathological progress.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Chronic limb ischemia; age-related macular degeneration; chronic heart failure; chronic oxidative stress; ictus; ozone therapy

Document Type: Research Article

Publication date: 2009-06-01

More about this publication?
  • Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more